Samsung Biologics to launch $1.8 billion all-cash bid for PolyPeptide

July 20 (Reuters) – South Korea's Samsung Biologics will launch a 1.46 billion Swiss francs ($1.81 billion) all-cash bid for Swiss contract drugmaker PolyPeptide, the companies said in separate

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)